--- title: "DiaMedica Therapeutics (DMAC) news: offering" url: "https://aibio.space/companies/diamedica-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "DMAC offering news: DiaMedica Therapeutics sets up $100.0 million at-the-market share program with TD Cowen. DiaMedica Therapeutics Inc." --- DMAC DiaMedica Therapeutics Inc. NASDAQ · United States # DiaMedica Therapeutics (DMAC) news DMAC offering news Financings · 2025-08-12 ## [DiaMedica Therapeutics sets up $100.0 million at-the-market share program with TD Cowen](https://aibio.space/news/diamedica-therapeutics-sets-up-100-0-million-market-share-program-td/) DiaMedica agreed to sell up to $100.0 million of common shares through TD Securities (USA) LLC, which can earn up to 3.0% of gross proceeds. No sale can be made until the Form S-3 is declared effective, and the filings give no cash balance. ## Latest DiaMedica Therapeutics news 1. 2025-07-21 Financings [DiaMedica Therapeutics agrees to $30.1 million private placement with existing stockholders](https://aibio.space/news/diamedica-therapeutics-agrees-30-1-million-private-placement-existing/) DiaMedica will sell 8,606,426 common shares at $3.50 each, for expected gross proceeds of $30.1 million before fees. The 8-K names no placement agent, and the company used $22,076 thousand in operations in 2024 while its equity fell to $40,718 thousand. ## DiaMedica Therapeutics at a glance - **Ticker**: DMAC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $43.5 million ### Related companies - [Biomolecular Life Holdings](https://aibio.space/companies/biomolecular-life/) OTC: BIOM - [UroGen Pharma](https://aibio.space/companies/urogen-pharma/) NASDAQ: URGN - [Black Diamond Therapeutics](https://aibio.space/companies/black-diamond-therapeutics/) NASDAQ: BDTX - [GRI Bio](https://aibio.space/companies/gri-bio/) NASDAQ: GRI - [Kymera Therapeutics](https://aibio.space/companies/kymera-therapeutics/) NASDAQ: KYMR - [Novavax](https://aibio.space/companies/novavax/) NASDAQ: NVAX - [Akari Therapeutics Plc](https://aibio.space/companies/akari-therapeutics/) NASDAQ: AKTX - [Rallybio](https://aibio.space/companies/rallybio/) NASDAQ: RLYB ### Also on NASDAQ - [Prenetics Global](https://aibio.space/companies/prenetics-global/) PRE - [ORGANIGRAM GLOBAL INC.](https://aibio.space/companies/organigram-global/) OGI - [Olema Pharmaceuticals](https://aibio.space/companies/olema-pharmaceuticals/) OLMA - [Braveheart Bio](https://aibio.space/companies/braveheart-bio/) BRVE - [Immunovant](https://aibio.space/companies/immunovant/) IMVT - [GeoVax Labs](https://aibio.space/companies/geovax-labs/) GOVX ## DiaMedica Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$24.6 million](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010342/) | [$19.1 million](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010342/) | | Net income (loss) | [-$32.8 million](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010342/) | [-$24.4 million](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010342/) | | Cash from operations | [-$29.1 million](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010342/) | [-$22.1 million](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010342/) | | Cash and equivalents | [$15.6 million](https://www.sec.gov/Archives/edgar/data/1401040/000143774926026792/) | [$3.0 million](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010342/) | | Short-term investments | [$44.2 million](https://www.sec.gov/Archives/edgar/data/1401040/000143774926026792/) | [$41.1 million](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010342/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.1 million, plus short-term investments of $38.4 million, $43.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about DiaMedica Therapeutics Has DiaMedica Therapeutics raised money recently? Our latest story on this, dated Aug 12, 2025: "DiaMedica Therapeutics sets up $100.0 million at-the-market share program with TD Cowen". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/diamedica-therapeutics-sets-up-100-0-million-market-share-program-td/). What is the ticker symbol of DiaMedica Therapeutics? DiaMedica Therapeutics Inc. trades under the ticker DMAC on NASDAQ. Where is DiaMedica Therapeutics listed? DiaMedica Therapeutics Inc. is listed on NASDAQ. What is the SEC CIK of DiaMedica Therapeutics? The SEC Central Index Key (CIK) for DiaMedica Therapeutics Inc. is 1401040. Its filings are on SEC EDGAR. How many shares does DiaMedica Therapeutics have outstanding? 53,925,697 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is DiaMedica Therapeutics listed under? Our directory records DiaMedica Therapeutics Inc. under United States. What does DiaMedica Therapeutics do? Our directory classifies DiaMedica Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of DiaMedica Therapeutics? The ISIN recorded for DiaMedica Therapeutics Inc. is CA25253X2077. Does aibio.space cover DiaMedica Therapeutics? aibio.space lists DiaMedica Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is DiaMedica Therapeutics incorporated? SEC records list its state or country of incorporation as Z4. Is DiaMedica Therapeutics profitable? DiaMedica Therapeutics Inc. reported a net loss of $32.8 million for the fiscal year ended Dec 31, 2025, and used $29.1 million of cash in operations, per its annual report to the SEC. How much does DiaMedica Therapeutics spend on research and development? $24.6 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does DiaMedica Therapeutics have? $43.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest DiaMedica Therapeutics (DMAC) stock news? Our latest story on DiaMedica Therapeutics, dated Aug 12, 2025: "DiaMedica Therapeutics sets up $100.0 million at-the-market share program with TD Cowen". DiaMedica agreed to sell up to $100.0 million of common shares through TD Securities (USA) LLC, which can earn up to 3.0% of gross proceeds. No sale can be made until the Form S-3 is declared effective, and the filings give no cash balance. [Source](https://aibio.space/news/diamedica-therapeutics-sets-up-100-0-million-market-share-program-td/). How long will DiaMedica Therapeutics's cash last? From our story of Aug 12, 2025: Neither the registration statement nor the 8-K gives a cash balance, a net loss or a cash runway, so the $100.0 million program cannot be set against the company's cash needs. [Source](https://aibio.space/news/diamedica-therapeutics-sets-up-100-0-million-market-share-program-td/). ## Investor discussion: DiaMedica Therapeutics Members talk about DiaMedica Therapeutics (DMAC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at DiaMedica Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-01-05 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1401040/000143774926000175/dmtp20260105_8k.htm) 2. 2025-08-12 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1401040/000143774925026273/dmtp20250811_s3.htm) 3. 2025-07-21 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1401040/000143774925023048/dmtp20250720_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:DMAC on TradingView](https://www.tradingview.com/symbols/NASDAQ-DMAC/). ## SEC filings and registration - **SEC name**: DiaMedica Therapeutics Inc. - **CIK**: 1401040 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: DMAC (Nasdaq) - **State or country of incorporation**: Z4 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 301 CARLSON PARKWAY, MINNEAPOLIS, MN, 55305 - **Phone**: (763) 496-5454 - **Shares outstanding**: 53,925,697 as of 2026-08-03 (10-Q filed 2026-08-10) - **Former names**: DiaMedica Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1401040/000143774926026792/dmtp20260630_10q.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1401040/000143774926026790/dmtp20260809_8k.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1401040/000143774926018106/dmtp20260520_8k.htm) filed 2026-05-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1401040/000143774926015220/dmtp20260331_10q.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1401040/000143774926015218/dmtp20260506_8k.htm) filed 2026-05-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010879/dmtp20260331_def14a.htm) filed 2026-04-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010409/dmtp20260330_8k.htm) filed 2026-03-31 - [10-K](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010342/dmtp20251231_10k.htm) filed 2026-03-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001401040), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details DiaMedica Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DMAC, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: DiaMedica Therapeutics Inc. - **Ticker**: DMAC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: CA25253X2077 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-DMAC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/diamedica-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "DiaMedica Therapeutics (DMAC) news: offering", 2026-10-31, https://aibio.space/companies/diamedica-therapeutics/